Case Report: Management of Recurrent Ovarian Squamous Cell Carcinoma With PD-1 Inhibitor

Xiao-Chen Song; Yong-Xue Wang; Mei Yu; Dong-Yan Cao; Jia-Xin Yang

doi:10.3389/fonc.2022.789228

Case Report: Management of Recurrent Ovarian Squamous Cell Carcinoma With PD-1 Inhibitor

Front Oncol. 2022 Mar 9:12:789228. doi: 10.3389/fonc.2022.789228. eCollection 2022.

Authors

Xiao-Chen Song¹, Yong-Xue Wang¹, Mei Yu¹, Dong-Yan Cao¹, Jia-Xin Yang¹

Affiliation

¹ Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Obstetrics & Gynecologic Diseases, Beijing, China.

Abstract

Malignant transformations, such as ovarian squamous cell carcinoma (SCC) in ovarian mature cystic teratoma (OMCT), are rare tumors. The management of recurrent disease is still a challenge, and the gene mutations involved remain unclear. We herein report a recurrent case of ovarian SCC with a PIK3CA gene variation and immunohistochemical staining of programmed death-ligand 1 (PD-L1) >10%. This patient achieved clinical remission after platinum-based effective chemotherapy and programmed death 1 (PD-1) immunotherapy.

Keywords: PD-1 inhibitor; chemotherapy; immunotherapy combined therapy; ovarian squamous cell carcinoma; recurrence.

Publication types

Case Reports